Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2025)

Historic Gross Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 88.8%.

  • Kiniksa Pharmaceuticals International's Gross Margin rose 67200.0% to 88.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.52%, marking a year-over-year increase of 12100.0%. This contributed to the annual value of 85.61% for FY2024, which is 20300.0% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Gross Margin of 88.8% as of Q3 2025, which was up 67200.0% from 88.14% recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Gross Margin's 5-year high stood at 104.52% during Q4 2022, with a 5-year trough of 67.99% in Q2 2021.
  • Its 5-year average for Gross Margin is 86.68%, with a median of 86.96% in 2022.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Gross Margin soared by 251500bps in 2022 and then plummeted by -160200bps in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Gross Margin (Quarter) stood at 79.37% in 2021, then soared by 32bps to 104.52% in 2022, then fell by -15bps to 88.51% in 2023, then decreased by -4bps to 85.4% in 2024, then rose by 4bps to 88.8% in 2025.
  • Its Gross Margin was 88.8% in Q3 2025, compared to 88.14% in Q2 2025 and 87.03% in Q1 2025.